Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide. Finnish medicine performance enhancing company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
